EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1

Beiping Miao, Zhaoqing Hu, Riccardo Mezzadra, Lotte Hoeijmakers, Astrid Fauster, Shangce Du, Zhi Yang, Melanie Sator-Schmitt, Helena Engel, Xueshen Li, Caroline Broderick, Guangzhi Jin und 28 weitere

Cancer Cell · 2023-10 · 41 (10) · 1817-1828.e9

DOI: 10.1016/j.ccell.2023.08.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2023-10. Verfasst von Beiping Miao und 39 weiteren Autor:innen. Beteiligte Einrichtung: German Cancer Research Center (DKFZ) Heidelberg, Division Immune Regulation in Cancer, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany; State Key …. Hauptthemen laut MEDLINE: B7-H1 Antigen, Neoplasms, T-Lymphocytes, Myelin Proteins. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, German Cancer Research Centre, European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The dysregulated expression of immune checkpoint molecules enables cancer cells to evade immune destruction. While blockade of inhibitory immune checkpoints like PD-L1 forms the basis of current cancer immunotherapies, a deficiency in costimulatory signals can render these therapies futile. CD58, a costimulatory ligand, plays a crucial role in antitumor immune responses, but the mechanisms controlling its expression remain unclear. Using two systematic approaches, we reveal that CMTM6 positively regulates CD58 expression. Notably, CMTM6 interacts with both CD58 and PD-L1, maintaining the expression of these two immune checkpoint ligands with opposing functions. Functionally, the presence of CMTM6 and CD58 on tumor cells significantly affects T cell-tumor interactions and response to PD-L1-PD-1 blockade. Collectively, these findings provide fundamental insights into CD58 regulation, uncover a shared regulator of stimulatory and inhibitory immune checkpoints, and highlight the importance of tumor-intrinsic CMTM6 and CD58 expression in antitumor immune responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenNeoplasmsT-LymphocytesMyelin ProteinsMARVEL Domain-Containing ProteinsHumansImmunityImmunotherapy

Substanzen

B7-H1 AntigenCMTM6 protein, humanMyelin ProteinsMARVEL Domain-Containing Proteins

Autor:innen und Institutionen

  • German Cancer Research Center (DKFZ) Heidelberg, Division Immune Regulation in Cancer, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute,…
  • German Cancer Research Center (DKFZ) Heidelberg, Division Immune Regulation in Cancer, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany; Faculty of Biosciences, Heidelberg University, 69120 Heidelberg, Germany.
  • Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Oncode Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cance…
  • Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Oncode Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.
  • Division of Biochemistry, Netherlands Cancer Institute, Oncode Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.
  • German Cancer Research Center (DKFZ) Heidelberg, Division Immune Regulation in Cancer, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany; Faculty of Medicine, Heidelberg University, 69120 Heidelberg, Germany.

Förderung

  • NCI NIH HHS
  • German Cancer Research Centre
  • European Union
  • German Research Foundation
  • KNAW
  • NWO
  • KWF Kankerbestrijding
  • NCT Heidelberg

Zitieren

APA

Miao, B., Hu, Z., Mezzadra, R., Hoeijmakers, L., Fauster, A., Du, S., Yang, Z., Sator-Schmitt, M., Engel, H., Li, X., Broderick, C., Jin, G., Gomez-Eerland, R., Rozeman, L., Lei, X., Matsuo, H., Yang, C., Hofland, I., Peters, D., …, & Sun, C. (2023). CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1. Cancer Cell, 41(10), 1817-1828.e9. https://doi.org/10.1016/j.ccell.2023.08.008

Vancouver

Miao B, Hu Z, Mezzadra R, Hoeijmakers L, Fauster A, Du S, et al. CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1. Cancer Cell. 2023;41(10):1817-1828.e9. doi:10.1016/j.ccell.2023.08.008

BibTeX
@article{Miao2023,
  author = {Miao, Beiping and Hu, Zhaoqing and Mezzadra, Riccardo and Hoeijmakers, Lotte and Fauster, Astrid and Du, Shangce and Yang, Zhi and Sator-Schmitt, Melanie and Engel, Helena and Li, Xueshen and Broderick, Caroline and Jin, Guangzhi and Gomez-Eerland, Raquel and Rozeman, Lisette and Lei, Xin and Matsuo, Hitoshi and Yang, Chen and Hofland, Ingrid and Peters, Dennis and Broeks, Annegien and Laport, Elke and Fitz, Annika and Zhao, Xiyue and Mahmoud, Mohamed A A and Ma, Xiujian and Sander, Sandrine and Liu, Hai-Kun and Cui, Guoliang and Gan, Yu and Wu, Wei and Xiao, Yanling and Heck, Albert J R and Guan, Wenxian and Lowe, Scott W and Horlings, Hugo M and Wang, Cun and Brummelkamp, Thijn R and Blank, Christian U and Schumacher, Ton N M and Sun, Chong},
  title = {CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1},
  journal = {Cancer Cell},
  year = {2023},
  volume = {41},
  number = {10},
  pages = {1817--1828.e9},
  doi = {10.1016/j.ccell.2023.08.008}
}
Kostenlos starten →